MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES.

MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES. - PLEIADES-pcsk9

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43374

Enrollment

Registered

2016-12-30

Start date

2017-11-27

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fat loading Postprandial lipemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age of 18 years or older - Male - Fasting triglycerides levels between 1.8 mmol/L and 7.0 mmol/L - Diabetes mellitus type 2 on intensive insulin treatment (three times short acting and one daily long acting) (unchanges for >10 weeks prior to consent) - Stable glucose regulation last 6 months (HbA1c >6.5% -

Exclusion criteria

Exclusion criteria: - Current smoking - Impaired renalfunction (MDRD 20 mmol/L requiring hospital admittance) - Recent or current use of pcsk9 antibodies - HIV-infection - Uncontrolled hypothyroidism

Design outcomes

Primary

Measure	Time frame
Postprandial leukocyte inflammation markers	—

Secondary

Measure	Time frame
Postprandial lipemia, oxidative stress parameters and vascular function.	—

Countries

Netherlands

Outcome results